Loading clinical trials...
Loading clinical trials...
Longitudinal Study of Cognition in Primary Progressive Multiple Sclerosis: a Cohort Study
Cognitive impairment is nowadays more and more recognized as an important feature of the multiple sclerosis (MS) disease. Cognitive disorders frequency in MS is estimated between 40 and 60%. Cognitive impairment affects quality of life and vocational status in MS patients. Until recently, little information was available on the cognitive dysfunction and their evolution that occur in primary progressive multiple sclerosis (PPMS) as compared with relapsing-remitting MS (RRMS). In PPMS pathological studies have shown the importance of cortical demyelination and meningeal inflammation suggesting that the GM alteration could play a major role in the cognitive impairment in this phenotype. The cognitive evolution and the brain tissue alteration at the origin of these difficulties remain poorly understood in PPMS. The use of new techniques for morphological and functional MRI can study the contribution of diffuse White Matter (WM) alteration (probably through disconnexion of relevant network) and diffuse Grey matter (GM) alterations in the cerebral cortex and other structures (the hippocampi, the cerebellum, and the thalami) in cognitive impairment in PPMS patients and on their evolution.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
Yes
CHU de Bordeaux
Bordeaux, France
CHU de Limoges
Limoges, France
CHU de Poitiers
Poitiers, France
Start Date
September 24, 2018
Primary Completion Date
March 1, 2026
Completion Date
March 1, 2026
Last Updated
February 3, 2026
66
ACTUAL participants
Clinical assessment
OTHER
Ecological evaluation
OTHER
Neuropsychological evaluation
OTHER
Psychological evaluation
OTHER
MRI Evaluation
DEVICE
Lead Sponsor
University Hospital, Bordeaux
Collaborators
NCT05359653
NCT06138132
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions